---

Therapeutic approaches in alzheimer’s disease: ? -amyloid peptide inhibitors

---

Review Article

Author Details : Chetna P Hiwase, Nikita S Bhandekar, Milind J Umekar, Krishna R Gupta*

Volume : 7, Issue : 3, Year : 2020

Article Page : 147-154

https://doi.org/10.18231/j.ijpp.2020.025

Suggest article by email

Get Permission

---

Abstract

In 2015, around 44 million people throughout the world, Dementia caused due to Alzheimer’s disease
(AD) is associated with a progressive neurodegenerative disorder and this figure is estimated to double
by the year 2050. Accumulation of b amyloid triggers the progression of AD through overproduction and
aggregation which actively induce synaptic dysfunction leading to disease expression. The generation of
Amyloid b -protein (Ab), occurs through sequential cleavage of b - and g -secretases while its removal is
dependent on the proteolysis and lysosomal degradation system. The present review is focused on the
treatments and strategies based on therapies being developed for treating AD which targets b - amyloid
protein. These prospects include agents acting on (Ab ), blocking Tau oligomerization, acetylcholinesterase
Inhibitors, N-Methyl-D-Aspartate Receptor (NMDA) antagonist. Targeting Amyloid b -protein (Ab ) (Anti-
Amyloid Approach), targeting amyloid aggregation, amyloid based vaccination therapy, Inhibition of Tau
Phosphorylation, targeting amyloid clearance and cholesterol lowering drug.

Keywords: Alzheimer’s disease, Amyloid peptide, Amyloid precursor protein, Biogenesis, Therapeutic β targets.

How to cite : Hiwase C P , Bhandekar N S, Umekar M J, Gupta K R, Therapeutic approaches in alzheimer’s disease: ? -amyloid peptide inhibitors. Indian J Pharm Pharmacol 2020;7(3):147-154

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.